Summary
This 10-K filing for Johnson & Johnson (JNJ) for the fiscal year ending December 28, 2003, highlights a robust diversified healthcare company with strong positions across its consumer, pharmaceutical, and medical devices/diagnostics segments. The company operates globally, demonstrating resilience and a commitment to innovation through its ongoing research and development efforts. Investors can take comfort in JNJ's established market presence, ongoing patent protections, and compliance with rigorous regulatory standards, all of which contribute to its stable financial footing and long-term growth prospects. The filing indicates JNJ is an accelerated filer, signaling a mature and well-established reporting process.
Key Highlights
- 1Johnson & Johnson operates through three primary segments: Consumer, Pharmaceutical, and Medical Devices and Diagnostics, showcasing a diversified revenue base.
- 2The company holds strong market positions and relies on patents and trademarks to protect its intellectual property and product exclusivity.
- 3JNJ is subject to extensive regulation across all its business segments, which is a standard but significant aspect of its operating environment.
- 4The filing indicates a significant market capitalization, with approximately $153 billion in market value of common stock held by non-affiliates as of the second fiscal quarter.
- 5Research and Development (R&D) is a key focus, underscoring the company's commitment to innovation and future product pipelines.
- 6JNJ has a global operational footprint, with business activities and sales across various geographic areas.